A headline result presented at ADA 2026 and flagged on Fatty Liver Day is worth a careful read: the SYNCHRONIZE-MASLD Phase 3 trial of survodutide - a dual GLP-1 and glucagon receptor agonist - moved weight, cardiometabolic markers, liver fat, and fibrosis-related measurements all at once. In 218 adults with obesity and at-risk MASLD, the 6-milligram dose produced a 12.2% body-weight reduction by week 48 against 1.0% on placebo, and the liver numbers moved in the same direction as the scale.
The reason this trial matters is the consistency across endpoints, not any single number. Weight fell, waist circumference fell 11.1 centimeters, systolic blood pressure fell 6.7 mmHg, and insulin resistance - measured by HOMA-IR - dropped 46.3%. On the liver side, 84.2% of participants achieved at least a 30% reduction in liver fat, and 61% normalized their liver fat content. ALT fell 36.8%, and liver stiffness on FibroScan dropped from 10.2 kPa to 7.0 kPa.
What the liver numbers actually mean
The liver-fat numbers are the part most people will quote, and they are worth reading precisely. A 30% relative reduction in liver fat is the threshold the field treats as clinically meaningful, and 84.2% cleared it. Normalization of liver fat - dropping below 5% on imaging - is a stronger bar, and 61% reached it. Those are the fat-reduction endpoints, and they are strong.
The stiffness number is the one that deserves a slower read. Liver stiffness on FibroScan is a non-invasive stand-in for fibrosis, and a drop from 10.2 to 7.0 kPa is a real movement in the right direction - but non-invasive markers are not the same as a biopsy, and the field’s next question, which the presenters name themselves, is whether these marker improvements translate into long-term histologic outcomes. The trial is a strong marker result, not a settled histology result.
Where the plate still fits
A medicine that moves weight and liver fat at once does not make the plate optional - it changes the context around it. The 12.2% weight loss on the drug came with appetite suppression, which means the food a person does eat has to carry more nutrition per bite. The Recommended column - lean protein, legumes, whole grains, olive oil, vegetables - is the pattern that protects muscle and steady blood sugar through weight loss, whether the weight loss comes from a medicine or from the plate alone.
The specific numbers keep it concrete. Salmon sits around 1.3 grams of saturated fat per 100 grams with omega-3s; rolled oats carry about 10 grams of fiber per 100 grams; plain nonfat Greek yogurt brings protein at about 0.12 grams of saturated fat per 100 grams. These are the foods that pair with a weight-loss drug rather than fight it.
How our editorial team read this
We read drug-trial stories with a standing rule: report the numbers, keep the medicine behind a clinician, and separate a marker result from a settled outcome. Our data editor verified the trial, the dose, and the endpoint structure, and we kept the framing on the split between the strong fat-reduction results and the still-open histology question. We did not present survodutide as a food-page recommendation, and we did not let the weight number read as a promise.
What we did do is place the plate where it belongs - as the daily lever that holds up under the medicine’s appetite effects, and as the primary tool for readers not on the drug. The honest line is that the trial is a strong multi-signal result, and the food pattern is the constant that works with or without it.
The practical takeaway
For someone with MASLD, the survodutide trial is evidence that the liver responds to more than one lever, and that weight and liver fat move together. The medicine is a clinician’s decision; the Recommended column is the plate that holds up either way. The database covers the food; the clinic covers the prescription; the trial explains why both matter.